TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: alcohol recidivism assessed by questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alcohol recidivism assessed by clinical interview
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alcohol recidivism assessed by urine ethyl glucuronide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alcohol recidivism assessed by blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-∞ (total area under the plasma drug concentration-time curve from time zero to infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax (maximum drug plasma concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of Hydrochlorothiazide (HCTZ) excreted in urine over 48 hours (Ae(0-48h))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: tumoral recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change from Baseline sputum culture at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Fasting sBA Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: levels of fluoride concentration in saliva and biofilm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive ROAT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of eye fixation during Affective Theory of Mind (ToM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of eye fixations during Affective Theory of Mind (ToM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: response times during Affective Theory of Mind (ToM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Secondary vivax attack
Endpoint domain: Adverse events/effects
Primary endpoint: Subjective improvement assessed with Fibromyalgia Impact Questionnaire Revised (FIQR)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Subjective improvement assessed with the A-14 Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Subjective improvement assessed with the Clinical Global Impression - Global Improvement (CGI-I) Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Distance between the contact point and the top of the papilla
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral edema volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of patients with Severity Adverse Events within 90 days
Endpoint domain: Adverse events/effects
Primary endpoint: Scores of bone healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Total polyp detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Success rate for the first attempt at insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in 17-item total severity score of the Clinician-Administered PTSD scale (CAPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improve muscle strengths
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical acne symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence rate in sonography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence rate clinically
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic linear changes in horizontal width of the alveolar ridge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance between Mini Invasive Assessment and Invasive Pleural Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pleural Fluid Cytological Analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absorption time of deuterated water
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impedance changes linked with position switch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBV vaccine completion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in delusions as measured by the Psyrats-D total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in hip-VTA IFC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in hip-LO IFC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Positive and Negative Syndrome Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phase-angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isokinetic Peak Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isokinetic Work
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl Meyer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tracking Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sepsis incidence in asymptomatic newborns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: success rate of complete resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Changes in platelets count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Resolution of anemia as assessed by Clinical Global Impression (CGI) - 2 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of anemia as assessed by ferritin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Resolution of anemia as assessed by TSAT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Who Experienced at Least One Grade Greater Than or Equal to (>=) 2 Treatment Emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Experienced at Least One Treatment Emergent Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Experienced at Least One AE Leading to Study Drug Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With at Least One Markedly Abnormal Value (MAV) for Hematologic Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of patients with Primary plan type
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: CMV Polymerase Chain Reaction (PCR) in amniotic fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Post-traumatic stress disorder
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Participant perception of prognostic estimate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in visual acuity (VA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plantar fasciia thickness reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plateau pressures generated by mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Pain on Numeric Pain Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Functional Disability on Oswestry Disability Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Area Under the Plasma Concentration-time Curve From Time 0 to 12 Hours (AUC12h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination Half-life (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Growth retardation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammatory Cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in neutralization antibody titre against influenza
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Implicit score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ongoing pregnancy with fetal heart beat at 10 weeks
Endpoint domain: Mortality/survival
Primary endpoint: New enamel caries lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Monocular best corrected distance visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in refractive cylinder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minutes of Moderate to Vigorous Intensity Physical Activity Per Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viral Load Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver test changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Fibromyalgia Impact Questionnaire-revised
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Painfree period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean of High Sensitivity Cardiac Troponin I (Hs-cTnI) Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prosthetic Weight bearing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of correct diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BOLD functional MRI signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Cycle 1 DLT
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetic (PK) Parameters of Adavosertib in Terms of Systemic Exposure, AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Meclizine plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical safety during coronary angiography
Endpoint domain: Adverse events/effects
Primary endpoint: Dose limited toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of hypothyroidism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in thyroid function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Injury incidence and severity
Endpoint domain: Adverse events/effects
Primary endpoint: Tei-index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Objective response rate (ORR: complete response + partial response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Blood levels of drug
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laboratory test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Xanthones in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Survival (OS) Rate at 9 Months
Endpoint domain: Mortality/survival
Primary endpoint: Trust in Physician score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Jefferson Scale of Perceived Physician Empathy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Comprehensive echo ordered
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Potassium changes in response to terbutaline infusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Paricalcitol Maximum Observed Plasma Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Two Consecutive Reductions at Least 30% From Baseline in iPTH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in muscle protein fractional synthetic rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in objective symptoms of non-specific vaginitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Movement of the hemiparetic upper extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with plasma HIV-1 RNA <50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in serum ferritin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: body weight of the target child
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diagnosis of Autism Spectrum Disorders (ASD) at 24 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving a Complete or Partial Hematological Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of Drug-related Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Colorectal adenoma detection rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Colorectal adenoma miss rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants With and Without Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Biomarkers of tobacco exposure as measured in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biomarkers of tobacco effect as measured in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biomarkers of tobacco exposure as measured in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematological and non-hematological organ toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Development of insertional mutagenesis or hematologic malignancy
Endpoint domain: Adverse events/effects
Primary endpoint: Development of replication competent lentivirus
Endpoint domain: Adverse events/effects
Primary endpoint: change in microvascular blood volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Amounts of total radioactivity excreted in bile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Metabolic profile of AZD0837 excreted in bile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Identification of previously unknown metabolites in bile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Global Functioning Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Sustained or symptomatic ventricular tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Acne severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Post-cancer diagnosis cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Effect sizes for MR parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in isotopic folate in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in isotopic folate in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under the Concentration-Time Curve (AUC 0-8h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 8-week survival of human T-cells
Endpoint domain: Mortality/survival
Primary endpoint: Time in sitting according to shift
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of steps according to shift
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Barriers for getting out of bed
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of fasting plasma glucose (FPG, mmol/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of OGTT 2 hour blood glucose (mmol/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of HbA1c (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of control rate of blood glucose (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Disability associated to low back pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in Quantitative Electroencephalogram (qEEG) Prefrontal Cordance (PFC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Occurrence of Acute and Chronic GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Engraftment Maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of success of peripheral venous cannulation at the first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: levels of antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Inter-reader Agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ventilator weaning days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Margin status in malignancies of the head and neck
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Patient-oriented Composite Endpoint (PoCE)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Regional Glucose Metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total Score on Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Complete Closure of the Index Ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Shoulder and Scapular Stabilizer Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline Freezing of Gait (FOG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline Stride Length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Yearly contact rate to general practice
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in peak flow meter reading
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Clearance of Sodium, Potassium, Creatinine, Magnesium, Chloride, Calcium, Phosphate and Uric Acid From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Urinary Excretion in a 24-hour Period of Sodium, Potassium, Magnesium, Chloride, Calcium, Phosphate, Creatinine, Uric Acid, Glucose From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Serum Osmolality From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Favorable Pathologic Response at Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in AST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from baseline in ALT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from baseline in ALP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from baseline in GGT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from baseline in serum total bilirubin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Subject with adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in PROMIS Pain Intensity Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PROMIS Pain Interference Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Safety and efficacy of MRI imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes